Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities
Net income (loss)	$ 287,967	$ (5,736,603)
Adjustments to reconcile net income (loss) to net cash used in operating activities
Depreciation and amortization	42,235	350,452
Non-cash interest expense		456,679
Gain on impairment adjustment	(2,079,575)
Stock compensation expense	188,237	211,122
Change in inventory reserve	(13,240)	256,814
Loss on deconsolidation of subsidiaries	75,138
Change in fair value of derivative liabilities		(12,694)
Change in fair value of EIB loan guaranty	46,584
Changes in operating assets and liabilities
Accounts receivable	65,348	(142,177)
Inventory	13,240	(195,029)
Other assets	97,622	3,498
Accounts payable	80,426	(157,139)
Accrued compensation and other liabilities	129,323	100,388
Deferred revenue	(17,355)	(97,929)
Net cash used in operating activities	(1,084,050)	(4,962,618)
Cash flows from investing activities
Purchases of property and equipment		(330,446)
Net cash used in investing activities		(330,446)
Cash flows from financing activities
Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs		6,974,050
Proceeds from issuance of preferred stock	200,000
Payments on debt		(2,229,560)
Payments on finance lease obligations	(280)	(841)
Net cash provided by financing activities	199,720	4,743,649
Effects of exchange rates on cash		150,186
Net decrease in cash and cash equivalents and restricted cash	(884,330)	(399,229)
Cash and cash equivalents and restricted cash at beginning of period	1,454,085	7,935,659
Cash and cash equivalents and restricted cash at end of period	569,755	7,536,430
Supplemental disclosure of cash flow information
Cash paid for interest		56,320
Supplemental disclosures of noncash investing and financing activities
Right-of-use assets acquired through operating leases		$ 801,321